查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1719238

琥珀酸美托洛尔市场－全球产业规模、份额、趋势、机会和预测，按销售通路、最终用途、地区和竞争细分，2020-2030 年

Metoprolol Succinate Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Sales Channel, By End Use, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024 年全球琥珀酸美托洛尔市场价值为 3.8291 亿美元，预计到 2030 年将达到 7.4529 亿美元，预测期内复合年增长率为 6.86%。琥珀酸美托洛尔是一种选择性β受体阻断剂，广泛用于治疗高血压、慢性心臟衰竭、心绞痛和心律不整等心血管疾病。其长效特性和临床疗效使其成为长期治疗的首选。全球心血管疾病负担的不断增加，加上医疗保健意识的不断增强和对具有成本效益的治疗方法的需求不断增长，极大地推动了市场的发展。专利到期后仿製药的出现提高了药品的可负担性并扩大了药品的取得管道，特别是在发展中国家。此外，医疗保健产业重视联合疗法以提高治疗效果和患者依从性，这进一步推动了对琥珀酸美托洛尔的需求。

市场概览
预测期 2026-2030
2024年市场规模 3.8291亿美元
2030年市场规模 7.4529亿美元
2025-2030 年复合年增长率 6.86%
成长最快的领域 直接的
最大的市场 亚太地区

关键市场驱动因素

製药业的成长

主要市场挑战

药品不良反应与诉讼风险

主要市场趋势

缓释剂型日益受到青睐

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：COVID-19 对全球琥珀酸美托洛尔市场的影响

第五章：全球琥珀酸美托洛尔市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 按销售管道（直接、间接）
    • 依最终用途（高血压、慢性心臟衰竭、心绞痛、心律不整、焦虑等）
    • 按地区
    • 按公司分类（2024）
  • 市场地图

第六章：北美琥珀酸美托洛尔市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美：国家分析
    • 美国
    • 墨西哥
    • 加拿大

第七章：欧洲琥珀酸美托洛尔市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲：国家分析
    • 法国
    • 德国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区琥珀酸美托洛尔市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲

第九章：南美洲琥珀酸美托洛尔市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第十章：中东与非洲琥珀酸美托洛尔市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA：国家分析
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 11 章：市场动态

  • 驱动程式
  • 挑战

第 12 章：市场趋势与发展

  • 合併与收购（如有）
  • 产品发布（如有）
  • 最新动态

第 13 章：全球琥珀酸美托洛尔市场：SWOT 分析

第 14 章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 顾客的力量
  • 替代产品的威胁

第 15 章：竞争格局

  • Granules India Limited
  • Surya Remedies Private Limited
  • Shubham Remedies
  • Sun Pharmaceutical Industries Ltd.
  • Dr. Reddy's Laboratories
  • ATUL BIOSCIENCE LTD
  • UNITED CHEMIE PVT LTD
  • Vasoya Industries Pvt. Ltd
  • Infocus Remedies Pvt Ltd
  • Alembic Pharmaceuticals Ltd

第 16 章：策略建议

第17章调查会社について・免责事项

简介目录
Product Code: 28611

Global Metoprolol Succinate Market was valued at USD 382.91 Million in 2024 and is expected to reach USD 745.29 Million by 2030 with a CAGR of 6.86% during the forecast period. Metoprolol succinate, a selective beta-blocker, is widely utilized for managing cardiovascular conditions such as hypertension, chronic heart failure, angina pectoris, and arrhythmias. Its long-acting profile and clinical efficacy make it a preferred option for long-term treatment. The increasing global burden of cardiovascular diseases, coupled with growing healthcare awareness and rising demand for cost-effective therapies, is significantly driving the market. The availability of generic alternatives following patent expirations has improved affordability and expanded access, particularly in developing countries. Moreover, the healthcare industry's emphasis on combination therapies to enhance treatment outcomes and patient compliance is further propelling demand for metoprolol succinate.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 382.91 Million
Market Size 2030USD 745.29 Million
CAGR 2025-20306.86%
Fastest Growing SegmentDirect
Largest MarketAsia Pacific

Key Market Drivers

Growth in Pharmaceutical Industry

The continuous expansion of the global pharmaceutical sector is a major catalyst for the growth of the metoprolol succinate market. With pharmaceutical revenues reaching approximately USD 1.6 trillion in 2023, the industry's size has become comparable to the GDP of large national economies. This growth is primarily attributed to the rising prevalence of cardiovascular diseases and other chronic conditions. Lifestyle-related risk factors, such as sedentary habits, unhealthy diets, and an aging global population, have led to a surge in hypertension and heart-related disorders. Cardiovascular diseases, which account for nearly 17.9 million deaths annually, have made beta-blockers like metoprolol succinate an essential component of treatment regimens. The demand for metoprolol succinate continues to rise as pharmaceutical companies increase production capacity and focus on developing user-friendly formulations, such as extended-release tablets, to improve compliance and outcomes.

Key Market Challenges

Adverse Drug Reactions and Litigation Risks

Despite its widespread use, metoprolol succinate is associated with certain adverse drug reactions (ADRs), which can impact its adoption and market perception. Common side effects include fatigue, dizziness, hypotension, and bradycardia, while rare but serious complications such as bronchospasm and heart block may also occur. These reactions, especially when experienced by patients managing long-term therapy, can raise safety concerns and lead to treatment discontinuation. Moreover, the occurrence of ADRs has contributed to an increase in legal challenges and liability risks for pharmaceutical companies. Lawsuits stemming from drug-related injuries or inadequate warnings can damage corporate reputation and lead to significant financial penalties. As a result, managing drug safety, ensuring transparent communication about side effects, and maintaining compliance with regulatory standards are critical to sustaining trust and market stability.

Key Market Trends

Growing Preference for Extended-Release Formulations

A notable trend in the metoprolol succinate market is the increasing shift toward extended-release (ER) formulations, which are designed to maintain consistent therapeutic levels over a 24-hour period. Products like TOPROL-XL exemplify this trend, offering once-daily dosing that enhances patient convenience and treatment adherence. ER formulations reduce the likelihood of missed doses and provide more stable blood pressure control, which is especially beneficial for individuals managing chronic cardiovascular conditions. The convenience and effectiveness of extended-release tablets make them a preferred option among both physicians and patients. This shift also aligns with the broader healthcare emphasis on long-term disease management and patient-centric care models, further supporting the adoption of ER versions of metoprolol succinate in clinical practice.

Key Market Players

  • Granules India Limited
  • Surya Remedies Private Limited
  • Shubham Remedies
  • Sun Pharmaceutical Industries Ltd.
  • Dr. Reddy's Laboratories
  • ATUL BIOSCIENCE LTD
  • UNITED CHEMIE PVT LTD
  • Vasoya Industries Pvt. Ltd
  • Infocus Remedies Pvt Ltd
  • Alembic Pharmaceuticals Ltd

Report Scope:

In this report, the Global Metoprolol Succinate Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Metoprolol Succinate Market, By Sales Channel:

  • Direct
  • Indirect

Metoprolol Succinate Market, By End Use:

  • Hypertension
  • Chronic Heart Failure
  • Angina Pectoris
  • Arrhythmias
  • Anxiety
  • Others

Metoprolol Succinate Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Metoprolol Succinate Market.

Available Customizations:

Global Metoprolol Succinate Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Metoprolol Succinate Market

5. Global Metoprolol Succinate Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Sales Channel (Direct, Indirect)
    • 5.2.2. By End Use (Hypertension, Chronic Heart Failure, Angina Pectoris, Arrhythmias, Anxiety, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Metoprolol Succinate Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Sales Channel
    • 6.2.2. By End Use
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Metoprolol Succinate Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Sales Channel
        • 6.3.1.2.2. By End Use
    • 6.3.2. Mexico Metoprolol Succinate Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Sales Channel
        • 6.3.2.2.2. By End Use
    • 6.3.3. Canada Metoprolol Succinate Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Sales Channel
        • 6.3.3.2.2. By End Use

7. Europe Metoprolol Succinate Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Sales Channel
    • 7.2.2. By End Use
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Metoprolol Succinate Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Sales Channel
        • 7.3.1.2.2. By End Use
    • 7.3.2. Germany Metoprolol Succinate Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Sales Channel
        • 7.3.2.2.2. By End Use
    • 7.3.3. United Kingdom Metoprolol Succinate Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Sales Channel
        • 7.3.3.2.2. By End Use
    • 7.3.4. Italy Metoprolol Succinate Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Sales Channel
        • 7.3.4.2.2. By End Use
    • 7.3.5. Spain Metoprolol Succinate Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Sales Channel
        • 7.3.5.2.2. By End Use

8. Asia Pacific Metoprolol Succinate Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Sales Channel
    • 8.2.2. By End Use
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Metoprolol Succinate Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Sales Channel
        • 8.3.1.2.2. By End Use
    • 8.3.2. India Metoprolol Succinate Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Sales Channel
        • 8.3.2.2.2. By End Use
    • 8.3.3. South Korea Metoprolol Succinate Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Sales Channel
        • 8.3.3.2.2. By End Use
    • 8.3.4. Japan Metoprolol Succinate Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Sales Channel
        • 8.3.4.2.2. By End Use
    • 8.3.5. Australia Metoprolol Succinate Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Sales Channel
        • 8.3.5.2.2. By End Use

9. South America Metoprolol Succinate Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Sales Channel
    • 9.2.2. By End Use
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Metoprolol Succinate Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Sales Channel
        • 9.3.1.2.2. By End Use
    • 9.3.2. Argentina Metoprolol Succinate Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Sales Channel
        • 9.3.2.2.2. By End Use
    • 9.3.3. Colombia Metoprolol Succinate Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Sales Channel
        • 9.3.3.2.2. By End Use

10. Middle East and Africa Metoprolol Succinate Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Sales Channel
    • 10.2.2. By End Use
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Metoprolol Succinate Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Sales Channel
        • 10.3.1.2.2. By End Use
    • 10.3.2. Saudi Arabia Metoprolol Succinate Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Sales Channel
        • 10.3.2.2.2. By End Use
    • 10.3.3. UAE Metoprolol Succinate Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Sales Channel
        • 10.3.3.2.2. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Metoprolol Succinate Market: SWOT Analysis

14. Porters Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Granules India Limited
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
    • 15.1.6. Key Personnel Details
    • 15.1.7. SWOT Analysis
  • 15.2. Surya Remedies Private Limited
  • 15.3. Shubham Remedies
  • 15.4. Sun Pharmaceutical Industries Ltd.
  • 15.5. Dr. Reddy's Laboratories
  • 15.6. ATUL BIOSCIENCE LTD
  • 15.7. UNITED CHEMIE PVT LTD
  • 15.8. Vasoya Industries Pvt. Ltd
  • 15.9. Infocus Remedies Pvt Ltd
  • 15.10. Alembic Pharmaceuticals Ltd

16. Strategic Recommendations

17. About Us & Disclaimer